Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean-Claire Limun Manalo is active.

Publication


Featured researches published by Jean-Claire Limun Manalo.


ACS Medicinal Chemistry Letters | 2012

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Kenneth D. Rice; Naing Aay; Neel Kumar Anand; Charles M. Blazey; Owen Joseph Bowles; Joerg Bussenius; Simona Costanzo; Jeffry Kimo Curtis; Steven Charles Defina; Larisa Dubenko; Stefan Engst; Anagha Abhijit Joshi; Abigail R. Kennedy; Angie I. Kim; Elena S. Koltun; Julie Lougheed; Jean-Claire Limun Manalo; Jean‐Francois Martini; John M. Nuss; Csaba J. Peto; Tsze H. Tsang; Peiwen Yu; Stuart Johnston

The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types. Mutations associated with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK. Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer. Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metabolism and safety profile versus PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (1). XL518 exhibits robust in vitro and in vivo potency and efficacy in preclinical models with sustained duration of action and is currently in early stage clinical trials.


Bioorganic & Medicinal Chemistry Letters | 2012

Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90

Joerg Bussenius; Charles M. Blazey; Naing Aay; Neel Kumar Anand; Arlyn Arcalas; Tae-Gon Baik; Owen Joseph Bowles; Chris A. Buhr; Simona Costanzo; Jeffrey K. Curtis; Steven Charles Defina; Larisa Dubenko; Timothy S. Heuer; Ping Huang; Christopher Jaeger; Anagha Abhijit Joshi; Abigail R. Kennedy; Angie I. Kim; Katherine Lara; Jae Lee; Jonathan Li; Julie Lougheed; Sunghoon Ma; Shiva Malek; Jean-Claire Limun Manalo; Jean‐Francois Martini; Garth McGrath; Monique Nicoll; John M. Nuss; Michael Pack

With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.


Expert Opinion on Therapeutic Patents | 2006

Raf modulators and methods of use

Neel Kumar Anand; Charles M. Blazey; Owen Joseph Bowles; Joerg Bussenius; Simona Costanzo; Jeffry Kimo Curtis; Larisa Dubenko; Abigail R. Kennedy; Steven Charles Defina; Angie I. Kim; Jean-Claire Limun Manalo; Csaba J. Peto; Kenneth D. Rice; Tsze H. Tsang; Anagha Abhijit Joshi

Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC50 values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.


Archive | 2006

Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases

Naing Aay; Neel Kumar Anand; Owen Joseph Bowles; Joerg Bussenius; Simona Costanzo; Jeffry Kimo Curtis; Larisa Dubenko; Anagha Abhijit Joshi; Abigail R. Kennedy; Angie Inyoung Kim; Elena S. Koltun; Jean-Claire Limun Manalo; Csaba J. Peto; Kenneth D. Rice; Tsze H. Tsang; Steven Charles Defina; Charles M. Blazey


Archive | 2004

Anaplastic lymphoma kinase modulators and methods of use

Neel Kumar Anand; Charles M. Blazey; Owen Joseph Bowles; Joerg Bussenius; Simona Costanzo; Jeffry Kimo Curtis; Larisa Dubenko; Abigail R. Kennedy; Richard George Khoury; Angie I. Kim; Jean-Claire Limun Manalo; Csaba J. Peto; Kenneth D. Rice; Tsze H. Tsang


Archive | 2006

Pyrimidinones as casein kinase II (CK2) modulators

Kenneth D. Rice; Neel Kumar Anand; Arlyn Arcalas; Charles M. Blazey; Joerg Bussenius; Wai Ki Vickey Chan; Hongwang Du; Sergey Epshteyn; Mohamed Abdulkader Ibrahim; Patrick Kearney; Abigail R. Kennedy; Moon Hwan Kim; Jean-Claire Limun Manalo; Csaba J. Peto; Tsze H. Tsang; Amy Lew Tsuhako; Peiwen Zhou; Elena S. Koltun


Archive | 2006

Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators

Kenneth D. Rice; Joerg Bussenius; Simona Costanzo; Abigail R. Kennedy; Angie Inyoung Kim; Jean-Claire Limun Manalo; Csaba J. Peto


Archive | 2006

Amino-pyrimidines as casein kinase ii (ck2) modulators

Kenneth D. Rice; Charles M. Blazey; Sergey Epshteyn; Mohamed Abdulkader Ibrahim; Henry William Beecroft Johnson; Abigail R. Kennedy; Jean-Claire Limun Manalo; Csaba J. Peto


Archive | 2010

Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture

Naing Aay; Arlyn Arcalas; Owen Joseph Bowles; Joerg Bussenius; Jeffry Kimo Curtis; Steven Charles Defina; Larisa Dubenko; Jason R. Harris; Eileen Jackson-Ugueto; Jean-Claire Limun Manalo; Angie Inyoung Kim; Michael Pack; Csaba J. Peto; Kenneth D. Rice; Tsze H. Tsang


Archive | 2010

Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases

Neel Kumar Anand; Charles M. Blazey; Owen Joseph Bowles; Chris A. Buhr; Joerg Bussenius; Jeffry Kimo Curtis; Steven Charles Defina; Larisa Dubenko; Jason R. Harris; Eileen Jackson-Ugueto; Anagha Abhijit Joshi; Angie Inyoung Kim; Amy Lew Tsuhaki; Sunghoon Ma; Jean-Claire Limun Manalo; Stephanie Ng; Csaba J. Peto; Kenneth D. Rice; Tsze H. Tsang; Cristiana A. Zaharia

Collaboration


Dive into the Jean-Claire Limun Manalo's collaboration.

Researchain Logo
Decentralizing Knowledge